Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 8, 2017

Primary Completion Date

October 14, 2020

Study Completion Date

October 14, 2020

Conditions
Metastatic Hormone-Receptor-Positive (HR+) Breast CancerHER2-Negative Breast CancerMetastatic Epithelial Ovarian Cancer
Interventions
DRUG

Ribociclib

Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)

DRUG

PDR001

Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.

DRUG

Fulvestrant

Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03294694 - Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | Biotech Hunter | Biotech Hunter